

Wellnex Life Limited (ASX:WNX)

Launch of medicinal cannabis brand Wellness Life for the growing Special Access Scheme (SAS)

Investment Highlights

- Wellnex Life with Joint Venture partner [OneLife Botanicals](#) has successfully launched new medicinal cannabis brand - [Wellness Life](#) with first prescriptions dispensed
- Wellness Life with its full range of medicinal cannabis products is available to be ordered by pharmacies via [The Entourage Effect](#)
- Appointment of Dr Mihindu Jayasuriya and Dr Tony Farag as clinical senior medical advisors for Wellness Life

Wellnex Life Limited (ASX) ("Wellnex Life" or the "Company"), is pleased to announce that with our joint venture partner OneLife Botanicals, it has successfully launched the new medicinal cannabis brand – Wellness Life. Wellness Life has commenced sales in July with product being prescribed by registered medical professionals in Australia and dispensed by pharmacies.

Wellness Life provides patients high quality Australian medicinal cannabis products, with distribution of Wellness Life being facilitated by one of Australia's largest medicinal cannabis distributors to pharmacies in the Entourage Effect.

Industry experts Dr Mihindu Jayasuriya and Dr Tony Farag have been appointed as senior medical advisors for Wellness Life to complement the previous appointment of Dr Sylvia Victor (as the lead on the JV) to both provide training, education and to prescribe Wellness Life products to patients.

Dr Jayasuriya and Dr Farag have commenced training to select pharmacies on the medicinal cannabis market and more specifically on Wellness Life. This will accelerate the knowledge on Wellness Life in both pharmacies and more importantly with registered practitioners which will increase the brand awareness in the medical community.

About Dr Mihindu Jayasuriya

Dr Mihindu Jayasuriya is widely recognised as one of Australia's leading medicinal cannabis physicians and has a formidable reputation as the former Chief Medical Officer of Australia's leading medical cannabis franchise groups.

Dr Jayasuriya is a distinguished medicinal cannabis practitioner who brings a wealth of experience to the sector, having treated over 3,000 patients and delivering patient-centered, evidence-based care that sets the standard in the industry.

About Dr Tony Farag

Dr Tony Farag is an experienced holistic Medical Doctor and Pharmacist who adopts a holistic approach to well-being. His passion & skillsets in Medicinal Cannabis as well as nutrition & supplements are quite unique and highly integrated for patients.

Dr Farag was raised in Melbourne and completed GP training but pursued his initial specialty of interest in Medicinal cannabis. He has also successfully consulted thousands of patients in this field, and is actively involved in innovating MC products as well as improving delivery of these medicines and technology.



About SAS Market

The Special Access Scheme (SAS) allows registered medical practitioners to prescribe medicinal cannabis products to patients not included on the Australian Register of Therapeutic Goods (ATRG) that can only be dispensed in a pharmacy.

The medicinal cannabis market in Australia is projected to reach USD 356.7 million in 2024, with a compound growth rate (CAGR) of 4.58% from 2024 to 2029, potentially reaching USD 446.3 million by 2029 ([Source: Statista](#)).

George Karafotias, CEO of Wellnex Life, commented, "The launch of Wellnex Life is an exciting development, and we are well positioned to take advantage of the growing demand for prescription medicinal cannabis. We have quality Australian product manufactured by OneLife Botanicals, an experienced team led by Dr Sylvia Victor and great partners which makes this project very exciting."

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNL)

For further information, please contact:

Wellnex Life Limited (ASX:WNL)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNL) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both complements and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/

For personal use only

WELLNEX